Foamix Pharmaceuticals, an Israeli biotech that is developing topical foam treatments for moderate-to-severe acne and impetigo, raised $40 million by offering 6.7 million shares (increased from 5.9 million) at $6, well below the $10-$12 range. Foamix Pharmaceuticals plans to list on the NASDAQ under the symbol FOMX. Foamix Pharmaceuticals initially filed confidentially on 5/20/2014. Barclays and Cowen & Company acted as lead managers on the deal.
